288 related articles for article (PubMed ID: 8965315)
1. [Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers].
Abadjian G; Antoun R
J Med Liban; 1996; 44(1):10-5. PubMed ID: 8965315
[TBL] [Abstract][Full Text] [Related]
2. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
3. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
[TBL] [Abstract][Full Text] [Related]
4. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
[TBL] [Abstract][Full Text] [Related]
5. Hormonal receptors, cell proliferation fraction (Ki-67) and c-erbB-2 amplification in breast cancer. Relationship between differentiation degree and axillary lymph node metastases.
Sirvent JJ; Santafé M; Salvadó MT; Alvaro T; Raventós A; Palacios J
Histol Histopathol; 1994 Jul; 9(3):563-70. PubMed ID: 7526910
[TBL] [Abstract][Full Text] [Related]
6. [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer].
Pilka R; Mícková I; Lubuský M; Dusková M; Rícánková M; Kudela M
Ceska Gynekol; 2008 Jul; 73(4):222-7. PubMed ID: 18711961
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Factors on the Positivity for Metastases of the Axillary Lymph Nodes from Primary Breast Cancer.
Kondov B; Kondov G; Spirovski Z; Milenkovikj Z; Colanceski R; Petrusevska G; Pesevska M
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Mar; 38(1):81-90. PubMed ID: 28593885
[TBL] [Abstract][Full Text] [Related]
8. Nup88 mRNA overexpression is associated with high aggressiveness of breast cancer.
Agudo D; Gómez-Esquer F; Martínez-Arribas F; Núñez-Villar MJ; Pollán M; Schneider J
Int J Cancer; 2004 May; 109(5):717-20. PubMed ID: 14999780
[TBL] [Abstract][Full Text] [Related]
9. pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
Schwartz LH; Koerner FC; Edgerton SM; Sawicka JM; Rio MC; Bellocq JP; Chambon P; Thor AD
Cancer Res; 1991 Jan; 51(2):624-8. PubMed ID: 1985778
[TBL] [Abstract][Full Text] [Related]
10. [Biomorphological features of "minimal" carcinomas selected from a series of 2077 breast cancer cases].
Martinazzi M; Mauri FM; Calandra C; Hotz AM; Crivelli F
Pathologica; 2000 Apr; 92(2):65-71. PubMed ID: 10838870
[TBL] [Abstract][Full Text] [Related]
11. Receptor status, proliferating activity, and c-erbB2 oncoprotein. An immunocytochemical evaluation in breast cancer.
Campani D; Sarnelli R; Fontanini G; Martini L; Cecchetti D; De Luca F; Squartini F
Ann N Y Acad Sci; 1993 Nov; 698():167-73. PubMed ID: 7904137
[No Abstract] [Full Text] [Related]
12. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.
Zhao S; Xu L; Liu W; Lv C; Zhang K; Gao H; Wang J; Ma R
Int J Clin Exp Pathol; 2015; 8(5):5744-8. PubMed ID: 26191291
[TBL] [Abstract][Full Text] [Related]
13. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.
Buck A; Schirrmeister H; Kühn T; Shen C; Kalker T; Kotzerke J; Dankerl A; Glatting G; Reske S; Mattfeldt T
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1317-23. PubMed ID: 12271413
[TBL] [Abstract][Full Text] [Related]
14. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas.
Hurlimann J; Gebhard S; Gomez F
Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
[TBL] [Abstract][Full Text] [Related]
18. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
[TBL] [Abstract][Full Text] [Related]
19. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
20. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study].
Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E
Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
